Literature DB >> 12431289

Pharmacological therapy after acute cervical spinal cord injury.

M N Hadley, B C Walters, P A Grabb, N M Oyesiku, G J Przybylski, D K Resnick, T C Ryken.   

Abstract

STANDARDS: There is insufficient evidence to support treatment standards. GUIDELINES: There is insufficient evidence to support treatment guidelines. OPTIONS: Treatment with methylprednisolone for either 24 or 48 hours is recommended as an option in the treatment of patients with acute spinal cord injuries that should be undertaken only with the knowledge that the evidence suggesting harmful side effects is more consistent than any suggestion of clinical benefit. GM-1 GANGLIOSIDE: STANDARDS: There is insufficient evidence to support treatment standards. GUIDELINES: There is insufficient evidence to support treatment guidelines. OPTIONS: Treatment of patients with acute spinal cord injuries with GM-1 ganglioside is recommended as an option without demonstrated clinical benefit.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12431289     DOI: 10.1097/00006123-200203001-00013

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  14 in total

1.  High dose methylprednisolone in the immediate management of acute, blunt spinal cord injury: what is the current practice in emergency departments, spinal units, and neurosurgical units in the UK?

Authors:  A E Frampton; C A Eynon
Journal:  Emerg Med J       Date:  2006-07       Impact factor: 2.740

2.  Vector-mediated expression of erythropoietin improves functional outcome after cervical spinal cord contusion injury.

Authors:  S Wang; Z Wu; P Chiang; D J Fink; M Mata
Journal:  Gene Ther       Date:  2011-11-03       Impact factor: 5.250

Review 3.  A review: the role of high dose methylprednisolone in spinal cord trauma in children.

Authors:  Janine N Pettiford; Jai Bikhchandani; Daniel J Ostlie; Shawn D St Peter; Ronald J Sharp; David Juang
Journal:  Pediatr Surg Int       Date:  2011-10-13       Impact factor: 1.827

4.  Spinal cord injury without radiographic abnormalities.

Authors:  Barbara Buldini; Angela Amigoni; Roberto Faggin; Anna Maria Laverda
Journal:  Eur J Pediatr       Date:  2005-10-19       Impact factor: 3.183

Review 5.  Erythropoietin in spinal cord injury.

Authors:  Georgios K Matis; Theodossios A Birbilis
Journal:  Eur Spine J       Date:  2008-11-22       Impact factor: 3.134

6.  Cellular transplants in China: observational study from the largest human experiment in chronic spinal cord injury.

Authors:  Bruce H Dobkin; Armin Curt; James Guest
Journal:  Neurorehabil Neural Repair       Date:  2006-03       Impact factor: 3.919

Review 7.  Basic advances and new avenues in therapy of spinal cord injury.

Authors:  Bruce H Dobkin; Leif A Havton
Journal:  Annu Rev Med       Date:  2004       Impact factor: 13.739

8.  Erythropoietin: recent developments in the treatment of spinal cord injury.

Authors:  Stephana Carelli; Giovanni Marfia; Anna Maria Di Giulio; Giorgio Ghilardi; Alfredo Gorio
Journal:  Neurol Res Int       Date:  2011-07-04

Review 9.  Hydrogels and Cell Based Therapies in Spinal Cord Injury Regeneration.

Authors:  Rita C Assunção-Silva; Eduardo D Gomes; Nuno Sousa; Nuno A Silva; António J Salgado
Journal:  Stem Cells Int       Date:  2015-06-01       Impact factor: 5.443

10.  Methylprednisolone for the Treatment of Patients with Acute Spinal Cord Injuries: A Propensity Score-Matched Cohort Study from a Canadian Multi-Center Spinal Cord Injury Registry.

Authors:  Nathan Evaniew; Vanessa K Noonan; Nader Fallah; Brian K Kwon; Carly S Rivers; Henry Ahn; Christopher S Bailey; Sean D Christie; Daryl R Fourney; R John Hurlbert; A G Linassi; Michael G Fehlings; Marcel F Dvorak
Journal:  J Neurotrauma       Date:  2015-07-17       Impact factor: 5.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.